Zura Bio Ltd（ZURA）财务数据ZURAZura Bio Ltd

Evaluating the bottom line, Zura Bio Ltd maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -72.10%, provide a clear picture of how effectively ZURA converts its operational activities into shareholder value.

In the context of the broader market, ZURA competes directly with industry leaders such as GALT and OGCP. With a market capitalization of $341.15M, it holds a significant position in the sector. When comparing efficiency, ZURA's gross margin of N/A stands against GALT's N/A and OGCP's N/A. Such benchmarking helps identify whether Zura Bio Ltd is trading at a premium or discount relative to its financial performance.

Zura Bio has reported consistent net losses, with a Q2 2026 net income loss of $26.3 million and a GAAP EPS of -0.21, indicating ongoing profitability challenges. The company's cash reserves are substantial at $205.1 million, which can support operations through at least the end of 2028, but the widening losses raise concerns.